2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 252-254
Access, Representation, Population Health, Treatment Considerations, Biological Therapies, Transplantation, Women’s Health, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Diseases, Bleeding and Clotting, Thrombotic Disorders, Immunology, Neutropenia, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pregnant, Young Adult
PAPER

725 Physiologic ferritin reference ranges increase diagnosis and treatment initiation of iron deficiency without anemia

Spandan Goel, Camille Morgan, PhD2, Katelyn Bland, MBA3, Alice Ma, MD4, Joshua Rivenbark, MD, PhD5, Steven W. Cotten, PhD6, Samuel Robert Wilson, MD, MSCR7, Amy Shaheen, MD, MSc8, Callie Berkowitz, MD9, Dana Neutze, MD, PhD10
1 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
2 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
3 UNC Health Alliance, Morrisville, North Carolina, United States
4 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
5 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
6 University of North Carolina at Chapel Hill, Chapel Hill, United States
7 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
8 UNC Health Alliance, Morrisville, North Carolina, United States
9 University of North Carolina at Chapel Hill, Chapel Hill, United States
10 University of North Carolina at Chapel Hill, Chapel Hill, United States

Background: Iron deficiency without anemia (IDWA) is increasingly recognized as a distinct cause of morbidity separate from iron deficient anemia (IDA), notably causing fatigue, poor exercise intolerance, impaired cognition, among other symptoms (Bruner et al., Lancet, 1996; Verdon et al., BMJ, 2003). Updated diagnostic criteria for IDWA in adults apply serum ferritin thresholds of <30ng/mL (Jäger et al, JAMA Netw Open. 2024, Pasricha et al., Lancet, 2021), yet many hospital systems continue to use percentile cutoffs from healthy volunteers for ferritin reference ranges, often lower than 30ng/mL. As such, IDWA is underdiagnosed and undertreated. In 2025, our hospital’s clinical laboratory updated lower limits of normal (LLN) of serum ferritin from 7.3 ng/mL in adult women and 10.5 ng/mL in adult men to 30 ng/mL for all adults; concurrently, electronic health record (EHR) system interventions were implemented to improve management of IDWA. In this study, we characterize the clinical impact of a physiologic serum ferritin reference range on diagnosis and treatment initiation of IDWA in adults in primary care settings.

Methods: This study was reviewed and approved by the UNC IRB (#25-1395). As IDWA is often first recognized by primary care providers, we focused our study population on adult patients who received primary care at two high-volume academic outpatient clinics (one family medicine and one internal medicine). We identified patients with serum ferritin <30ng/mL at a visit occurring during one-month periods six months before and six months after the reference range update. We further restricted the population to patients without anemia, defined using current LLN of hemoglobin (≥11.4g/dL in women and ≥12.9 g/dL in men). Using chart reviews, we retrieved serum ferritin, hemoglobin, age, sex, menstruating status, iron deficiency diagnoses in provider communication, treatment of iron deficiency, counseling of the diagnosis, and additional consultations and referrals. We estimated absolute differences and number needed to treat (NNT) of IDWA diagnosis and IDWA treatment initiation comparing a physiologic ferritin reference range (post-update) to non-physiologic ranges (pre-update).

Results: In total, 235 patients met inclusion criteria for iron deficiency without anemia (109 pre-update and 126 post-update), 210 (89%) of whom were female. Median age was 40 years (IQR: 28, 52). Prior to the reference range update, 65 (60%) were diagnosed with iron deficiency by their primary care provider, and 61 (56%) were recommended treatment with over-the-counter iron supplementation (n=41), prescribed oral iron (n=10), or IV iron (n=10). About half (52%) were counseled on the diagnosis, including discussion of possible causes, dietary changes, or side effects of treatment. After the reference range change, 121 (96%) were diagnosed with iron deficiency by their primary care provider, and 115 (91%) were recommended treatment with over-the-counter iron supplementation (n=69), prescribed oral (n=20), or IV iron (n=25); 87% were counseled on the diagnosis. A physiologic ferritin reference range at the time of primary care evaluation was associated with 36 (95% CI: 27, 46) more diagnoses of iron deficiency without anemia per 100 patients compared with a non-physiologic ferritin reference range, equivalent to an NNT of 3 (95% CI: 3, 4). Similarly, a physiologic range was associated with 35 (95% CI: 25, 46) more patients per 100 initiated on treatment for IDWA compared with a non-physiologic range, for an NNT of 3 (95% CI: 3, 4).

Conclusions: Physiologic ferritin reference ranges were associated with a higher prevalence of diagnosis and treatment of IDWA. Updating laboratory thresholds alerts providers to abnormalities and represents a straightforward, systems-based approach to improving recognition and initiation of treatment in primary care settings. Analysis is ongoing for further workup of iron deficiency, including referrals to gastroenterology, gynecology, or hematology, and a similar effort is in progress for pediatric patients. While this study did not evaluate longitudinal management or outcomes of treatment on symptom improvement, implementing physiologic ferritin reference ranges may represent an important first step toward improving outcomes for patients with IDWA.

Spandan Goel: No relevant conflicts of interest to declare.